Key Question Answer

Global Market Outlook

In-depth analysis of global and regional trends

Analyze and identify the major players in the market, their market share, key developments, etc.

To understand the capability of the major players based on products offered, financials, and strategies.

Identify disrupting products, companies, and trends.

To identify opportunities in the market.

Analyze the regional penetration of players, products, and services in the market.

Comparison of major players financial performance.

Evaluate strategies adopted by major players.

Recommendations

Anti-inflammatory Drugs

The global anti-inflammatory drugs market was evaluated at US$ XX billion in 2023 and is expected to attain around US$ XX billion by 2033, growing at a CAGR of XX% from 2024 to 2033. The growth of the anti-inflammatory drugs market is significantly driven by the main goals of pain control, improved function, and enhanced health-related quality of life in patients. Nonsteroidal anti-inflammatory drugs (NSAIDs) stand out as the most commonly prescribed medications for managing musculoskeletal pain. Their clinical utility in alleviating mild-to-moderate pain is pivotal, balancing efficacy with considerations for potential side effects. This balanced approach underscores the expanding demand for anti-inflammatory drugs, fueled by the increasing emphasis on enhancing patient outcomes through effective pain management strategies.
Market Overview
The anti-inflammatory drugs market is experiencing rapid growth driven by their ability to reduce inflammation—a process involving the suppression of substances in the body that trigger swelling, pain, and redness. These drugs, particularly non-steroidal anti-inflammatory drugs (NSAIDs), exert their therapeutic effects by inhibiting cyclooxygenase (COX), an enzyme responsible for producing prostaglandins (PGs) implicated in inflammation. While COX-1 generates PGs that protect the stomach and kidney, COX-2 induces PGs contributing to inflammation-related pain and swelling. NSAIDs are widely used across various painful conditions, although their prescription requires caution due to potential serious adverse effects, even with short-term use. In primary care settings, paracetamol is preferred over NSAIDs unless otherwise indicated, with naproxen or ibuprofen recommended as first-line treatments at the lowest effective dose and duration possible. This market overview highlights the broad application and careful management of anti-inflammatory drugs in healthcare practices, emphasizing their significant role in therapeutic strategies worldwide.

• In January 2023, Sun Pharma acquired Disperzyme and Phlogam brands to strengthen its anti-inflammatory portfolio

Key Insights

•    North America has captured the highest market share.
•    By drug class, the anti-inflammatory biologics segment holds the largest share of the market.
•    By application, the autoimmune inflammatory illness segment dominated the market.
•    By End-user, the hospital pharmacy segment is expected to grow at a significant rate during the forecast period.

Regional Stance
The North American region holds a dominant position in the anti-inflammatory drugs market, driven significantly by the widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs constitute one of the most commonly utilized drug classes globally, with over 30 million people estimated to use them daily and accounting for 60% of the analgesic market in the United States alone. The U.S. market offers approximately 20 different NSAIDs available over-the-counter (OTC) and via prescription. In Canada, about 29% of the population uses prescription NSAIDs, alongside many more using OTC variants. Physiotherapists in Canada often recommend NSAIDs as part of comprehensive treatment plans to manage pain and inflammation in patients with musculoskeletal conditions or injuries. As primary-contact health professionals, Canadian physiotherapists play a pivotal role in advising on NSAID usage, reflecting the widespread integration of NSAIDs into physiotherapy practices and underscoring their prominence in North America's healthcare landscape.

• In March 2023, Sandoz received US FDA approval for biosimilar Hyrimoz (adalimumab-adaz) high-concentration formulation
Source: https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation.

The Asia-Pacific region is witnessing a robust growth in the anti-inflammatory therapeutic market driven by several factors including exponential population growth, increased healthcare expenditures, and rising prevalence of chronic, lifestyle-related, respiratory, and infectious diseases. In India, specifically in regions like Chhattisgarh, there is a notable lack of comprehensive data on NSAID utilization patterns, particularly in tertiary care centers. Addressing this gap is crucial to promoting more rational prescribing practices. A study was undertaken to assess the drug utilization patterns of NSAIDs at a newly established tertiary care teaching hospital in Raipur, Chhattisgarh, aiming to align these patterns with standardized WHO prescribing indicators. This initiative seeks to optimize prescribing practices and enhance healthcare delivery, reflecting the evolving dynamics of the anti-inflammatory therapeutic market in the Asia-Pacific region.

Report Highlights
By Drug Class
The anti-inflammatory drug market is segmented into corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and anti-inflammatory biologics based on medication class. Among these, the anti-inflammatory biologics sector commands the largest share. These biologic agents are specifically designed to treat rheumatological disorders by targeting proteins that trigger inflammation, unlike conventional disease-modifying antirheumatic drugs (DMARDs) which broadly suppress the immune system. While biologics offer potent anti-inflammatory effects that can halt joint and organ damage in conditions like arthritis, they also carry risks such as respiratory infections and non-infectious pulmonary diseases. This segment underscores the growing prominence of targeted therapies in managing chronic inflammatory conditions, reflecting advancements in precision medicine within the pharmaceutical industry.

By Application
The pharmaceutical market is segmented into autoimmune inflammatory disorders, respiratory illnesses, and other diseases based on application. Among these, autoimmune inflammatory illnesses, such as rheumatoid arthritis and psoriasis, are expected to lead in revenue generation. Medications targeting these conditions aim to regulate the immune system while preserving organ function. For instance, anti-TNF medications specifically target tumor necrosis factor (TNF), a protein that triggers inflammation, and are utilized in the treatment of autoimmune arthritis and psoriasis. nonsteroidal anti-inflammatory drugs (NSAIDs) are employed to alleviate pain, swelling, and stiffness associated with these disorders. This segment highlights the significant market opportunity in addressing autoimmune inflammatory conditions, driven by advancements in therapeutic approaches that balance immune modulation with organ support.

The respiratory diseases market, driven by increasing inhalation of corticosteroids among COPD patients, is poised for continuous growth in the forecast period. Anti-inflammatory medications play a crucial role in reducing airway inflammation, swelling, and mucus production, thereby decreasing airway sensitivity to triggers. These medications offer varied onset times for symptom relief, with some providing immediate relief and others requiring prolonged daily use to achieve comprehensive symptom control. By minimizing symptoms, improving airflow, and reducing airway damage, anti-inflammatories, particularly corticosteroids, are pivotal in managing COPD effectively. This application insight underscores the significant therapeutic benefits of anti-inflammatory treatments in enhancing respiratory health outcomes and addressing the evolving needs of patients with chronic respiratory conditions.

By Distribution Channel
In the distribution channels of the anti-inflammatory drug market, which include hospital pharmacies, retail pharmacies, and internet pharmacies, the hospital pharmacy sector has emerged as a leader. This is attributed to the increasing demand for anti-inflammatory medications, favorable health reimbursement policies, and the rising prevalence of inflammatory conditions. Non-steroidal anti-inflammatory drugs (NSAIDs), a prominent category in this market, have been associated with a higher rate of emergency hospital admissions due to adverse drug reactions compared to other drug classes. Addressing this challenge involves ensuring that patients receive clear guidance on the safe and effective use of NSAIDs. By promoting patient education on proper NSAID administration, healthcare providers can mitigate risks associated with these medications and optimize patient outcomes in the management of inflammatory diseases.

The over-the-counter (OTC) medicine market is poised for expansion driven by growing demand for popular NSAIDs like ibuprofen and diclofenac, coupled with increased availability of OTC drugs. NSAIDs such as aspirin, ibuprofen (Advil, Motrin), and naproxen (Aleve, Naprosyn) are examples of non-prescription anti-inflammatories widely accessible in retail settings. Despite their OTC status, these medications are highly effective in alleviating pain, reducing swelling, and lowering fever. The convenience and accessibility of OTC anti-inflammatories contribute significantly to their widespread use and adoption by consumers seeking immediate relief from common ailments. This trend underscores the pivotal role of retail pharmacies and other distribution channels in facilitating consumer access to essential OTC medications for managing inflammatory conditions.

Market Dynamics
Driver
Clinical Efficacy of Anti-inflammatory Drugs
The clinical efficacy of non-aspirin NSAIDs in acute pain management, comparable to starting doses of opioids but with a distinct ceiling dose effect, serves as a significant driver for the anti-inflammatory drugs market. Unlike opioids, which pose risks of addiction and overdose, NSAIDs provide analgesic relief without the ceiling effect for their anti-inflammatory properties. Studies in arthritis patients have highlighted the efficacy of non-aspirin NSAIDs such as diclofenac and celecoxib in reducing pain, joint swelling, morning stiffness, and improving mobility compared to acetaminophen. These findings underscore the growing preference for NSAIDs in clinical practice, contributing to the expanding market for anti-inflammatory medications aimed at enhancing patient outcomes and comfort in acute pain management scenarios.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646740/
Restraints
Risk of Adverse Effects
The widespread use of NSAIDs is tempered by their potential for serious adverse effects such as cardiovascular events, gastrointestinal complications, renal failure, and hypersensitivity reactions. Despite the relatively low individual risk for each patient, the cumulative use of NSAIDs across communities heightens the overall concern for adverse events. This necessitates careful evaluation of individual patient risk factors before prescribing NSAIDs, thereby posing a restraint on the growth of the anti-inflammatory drugs market. Healthcare providers must balance the therapeutic benefits of NSAIDs with their associated risks, ensuring patient safety and regulatory compliance in clinical practice.

Opportunities
Advancements in Targeted Drug Delivery
The development of novel disease-targeted drug delivery strategies promises enhanced therapeutic efficacy in treating and preventing inflammatory diseases. By focusing on specific molecular pathways and minimizing systemic side effects, these advancements offer substantial opportunities for growth in the anti-inflammatory drugs market. Progressive research efforts aimed at understanding molecular mechanisms underlying inflammation contribute to the development of innovative therapies that improve treatment outcomes and patient care, driving the expansion of the market for anti-inflammatory drugs.

• In March 2024, Avalo secured a novel anti-inflammatory drug through the AlmataBio buyout

Recent Developments

•    In April 2024, Alvotech and Teva announced the US FDA approval of SELARSDI (ustekinumab-aekn), a biosimilar to Stelara (ustekinumab)
•    In June 2024, EpiEndo and AlveoliX provided an update on their partnership aimed at pioneering ulcerative colitis treatment
•    In March 2022, Pfizer completed the acquisition of Arena Pharmaceuticals
Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals.

Key Players in the Anti-inflammatory Drugs Market
Eli Lily and Company
AstraZeneca PLC, Amgen Inc.
F. Hoffman, Abbvie, Inc.
Johnson & Johnson
GlaxoSmithKline
Merck & CO., Inc.
Novartis
Pfizer, Inc.
La Roche AG
Ferring Pharmaceuticals
Bioventus
Zimmer Biomet Holdings, Inc.
Flexion Therapeutics, Inc

Market Segmentation
•    By Drug Class
o    Anti-inflammatory Biologics
o    Non-steroidal Anti-inflammatory Drugs (NSAIDs)
o    Corticosteroids

•    By Indication
o    Arthritis
o    Rheumatoid Arthritis
o    Osteoarthritis
o    Ankylosing Spondylitis
o    Psoriatic Arthritis
o    Gout
o    Respiratory diseases
o    Asthma
o    Chronic obstructive pulmonary disease (COPD)
o    Multiple sclerosis
o    Psoriasis
o    Inflammatory bowel disease
o    Crohn's Disease
o    Ulcerative Colitis
o    Other inflammatory diseases

•    By Application
o    Autoimmune
o    Inflammatory Diseases (Rheumatoid Arthritis Psoriasis)
o    Respiratory Diseases
•    By Distribution Channel
o    Hospital Pharmacy
o    Retail Pharmacy

By Geography
o    North America
o    U.S.
o    Canada
o    Europe
o    Germany
o    France
o    United Kingdom
o    Rest of Europe
o    Asia Pacific
o    China
o    Japan
o    India
o    Southeast Asia
o    Rest of Asia Pacific
o    Latin America
o    Brazil
o    Rest of Latin America
o    Middle East & Africa (MEA)
o    GCC
o    North Africa
o    South Africa
o    Rest of Middle East & Africa

Choose License Type

Single User

$3999
Multi User

$5550
Enterprise User

$6999

Request Sample Ask For Customization Check Discount Speak TO Analyst Inquiry Before Buying

Our Reports Look Like This

HAVE A QUESTION

will help you find what you are looking for:

+91 7821962914

Global Anti-inflammatory Drugs Market

Report ID : 555

Category : Pharmaceuticals,Global

No Of Pages : 200

Published on: July 2024

Status: Published

Format :

Choose License Type

Our Reports Look Like This

HAVE A QUESTION

Related Reports

Recent Reports

Global Skincare Treatment Market

Published on October 2024

$ 3999

Non Steroidal Anti-Inflammatory Drugs (NSAIDs) Market

Published on April 2024

$ 3999

Global Organ Care Products Market

Published on December 2024

$ 3999

Active Pharmaceutical Ingredient Market

Published on July 2024

$ 3999

Anti Psychotic Drugs Market

Published on April 2024

$ 3999

North America Diabetic Foot Ulcer Treatment Market

Published on November 2024

$ 3999

Free Sample Request

Alternative Text

Subscribe to Newsletter